FOLH1 and prostate carcinoma: With regard to such developments, when the Advanced Prostate Cancer Consensus Conference discussed questions relating to 223Ra and other therapies in 2021, consensus was reached that using 223Ra after 177Lu-PSMA is safe (76% consensus), based on outcomes from VISION, in which approximately 2.5% of patients received 223Ra following 177Lu-PSMA therapy (74).